Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-22

Clinical Trial Update: Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing Macular Epiretinal Brachytherapy to Lucentis-only treatment for macular degeneration; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)
  • Macular Epiretinal Brachytherapy (not specified)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-07-22